UA95284C2 - Антитела к рецептору инсулинподобного фактора роста i и их применение - Google Patents

Антитела к рецептору инсулинподобного фактора роста i и их применение

Info

Publication number
UA95284C2
UA95284C2 UAA200812606A UAA200812606A UA95284C2 UA 95284 C2 UA95284 C2 UA 95284C2 UA A200812606 A UAA200812606 A UA A200812606A UA A200812606 A UAA200812606 A UA A200812606A UA 95284 C2 UA95284 C2 UA 95284C2
Authority
UA
Ukraine
Prior art keywords
receptor
growth factor
antibodies against
amount
against insulin
Prior art date
Application number
UAA200812606A
Other languages
English (en)
Russian (ru)
Ukrainian (uk)
Inventor
Зильке Хансен
Клаус-Петер Кюнкеле
Дитмар Ройш
Ральф Шумахер
Original Assignee
Ф. Хоффманн-Ля Рош Аг
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=36940705&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=UA95284(C2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Ф. Хоффманн-Ля Рош Аг filed Critical Ф. Хоффманн-Ля Рош Аг
Publication of UA95284C2 publication Critical patent/UA95284C2/ru

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2863—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for growth factors, growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/22—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against growth factors ; against growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/40—Immunoglobulins specific features characterized by post-translational modification
    • C07K2317/41—Glycosylation, sialylation, or fucosylation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
UAA200812606A 2006-04-11 2007-04-10 Антитела к рецептору инсулинподобного фактора роста i и их применение UA95284C2 (ru)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP06007571 2006-04-11

Publications (1)

Publication Number Publication Date
UA95284C2 true UA95284C2 (ru) 2011-07-25

Family

ID=36940705

Family Applications (1)

Application Number Title Priority Date Filing Date
UAA200812606A UA95284C2 (ru) 2006-04-11 2007-04-10 Антитела к рецептору инсулинподобного фактора роста i и их применение

Country Status (20)

Country Link
US (1) US20080014203A1 (enExample)
EP (2) EP2363417A1 (enExample)
JP (1) JP4718634B2 (enExample)
KR (2) KR20120028396A (enExample)
CN (1) CN101421305B (enExample)
AR (1) AR060592A1 (enExample)
AU (1) AU2007236199B2 (enExample)
BR (1) BRPI0710185B8 (enExample)
CA (2) CA3081707A1 (enExample)
CR (1) CR10301A (enExample)
EC (1) ECSP088816A (enExample)
ES (1) ES2403075T3 (enExample)
IL (1) IL194397A (enExample)
MX (1) MX2008012950A (enExample)
NO (1) NO20084082L (enExample)
NZ (1) NZ571414A (enExample)
RU (1) RU2541765C2 (enExample)
UA (1) UA95284C2 (enExample)
WO (1) WO2007115814A2 (enExample)
ZA (1) ZA200808597B (enExample)

Families Citing this family (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7846724B2 (en) 2006-04-11 2010-12-07 Hoffmann-La Roche Inc. Method for selecting CHO cell for production of glycosylated antibodies
WO2008079849A2 (en) * 2006-12-22 2008-07-03 Genentech, Inc. Antibodies to insulin-like growth factor receptor
PE20090368A1 (es) 2007-06-19 2009-04-28 Boehringer Ingelheim Int Anticuerpos anti-igf
WO2009080278A1 (en) 2007-12-21 2009-07-02 F. Hoffmann-La Roche Ag Stability testing of antibodies
UY32317A (es) 2008-12-12 2010-07-30 Boehringer Ingelheim Int Anticuerpos anti-igf
WO2010112194A1 (en) * 2009-04-02 2010-10-07 F. Hoffmann-La Roche Ag Antigen-binding polypeptides and multispecific antibodies comprising them
WO2010146059A2 (en) 2009-06-16 2010-12-23 F. Hoffmann-La Roche Ag Biomarkers for igf-1r inhibitor therapy
EP2456547B2 (en) 2009-07-24 2024-03-06 F. Hoffmann-La Roche AG Stirrer system
EP2486055A4 (en) * 2009-10-07 2013-04-17 Us Health HUMAN ANTIBODIES AGAINST COMPONENTS OF THE SYSTEM OF THE HUMAN INSULINARY GROWTH FACTOR (IGF)
US20110117087A1 (en) 2009-10-26 2011-05-19 Reinhard Franze Method for the production of a glycosylated immunoglobulin
US20110200595A1 (en) 2010-02-18 2011-08-18 Roche Glycart TREATMENT WITH A HUMANIZED IgG CLASS ANTI EGFR ANTIBODY AND AN ANTIBODY AGAINST INSULIN LIKE GROWTH FACTOR 1 RECEPTOR
WO2011135040A1 (en) 2010-04-30 2011-11-03 F. Hoffmann-La Roche Ag Fluorescent antibody fusion protein, its production and use
WO2012059495A1 (en) 2010-11-05 2012-05-10 F. Hoffmann-La Roche Ag Optimized method for antibody capturing by mixed mode chromatography
PL2723773T3 (pl) 2011-06-22 2018-07-31 F.Hoffmann-La Roche Ag Eliminacja komórek docelowych przez obecne w krążeniu, swoiste dla wirusa, cytotoksyczne limfocyty T z wykorzystaniem kompleksów zawierających MHC klasy I
RU2502798C2 (ru) * 2012-02-22 2013-12-27 Общество с ограниченной ответственностью "Фармако Биотех" КЛЕТОЧНАЯ ЛИНИЯ huFSHIK, СЕКРЕТИРУЮЩАЯ РЕКОМБИНАНТНЫЙ ЧЕЛОВЕЧЕСКИЙ ФСГ
EP2727941A1 (en) 2012-11-05 2014-05-07 MAB Discovery GmbH Method for the production of multispecific antibodies
WO2014067642A1 (en) 2012-11-05 2014-05-08 Mab Discovery Gmbh Method for the production of multispecific antibodies
JP6475167B2 (ja) 2012-12-21 2019-02-27 エフ．ホフマン−ラ ロシュ アーゲーＦ． Ｈｏｆｆｍａｎｎ−Ｌａ Ｒｏｃｈｅ Ａｋｔｉｅｎｇｅｓｅｌｌｓｃｈａｆｔ ジスルフィド結合した多価ｍｈｃクラスｉを含む多機能タンパク質
US20140255413A1 (en) 2013-03-07 2014-09-11 Boehringer Ingelheim International Gmbh Combination therapy for neoplasia treatment
WO2021119234A1 (en) * 2019-12-10 2021-06-17 Horizon Pharma Ireland Ltd. Glycosylated antibodies against insulin-like growth factor i receptor and uses thereof
CA3195512A1 (en) 2020-10-14 2022-04-21 Vahe Bedian Compositions and methods for treatment of thyroid eye disease
JP2024531151A (ja) 2021-08-10 2024-08-29 ビリジアン セラピューティクス， インコーポレイテッド 甲状腺眼疾患の処置のための組成物、用量および方法

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4675187A (en) 1983-05-16 1987-06-23 Bristol-Myers Company BBM-1675, a new antibiotic complex
US5204244A (en) * 1987-10-27 1993-04-20 Oncogen Production of chimeric antibodies by homologous recombination
US5202238A (en) * 1987-10-27 1993-04-13 Oncogen Production of chimeric antibodies by homologous recombination
US5770429A (en) * 1990-08-29 1998-06-23 Genpharm International, Inc. Transgenic non-human animals capable of producing heterologous antibodies
GB9022543D0 (en) * 1990-10-17 1990-11-28 Wellcome Found Antibody production
US5650508A (en) * 1991-12-27 1997-07-22 Georgia Tech Research Corporation Peptide ketoamides
ATE139900T1 (de) 1992-11-13 1996-07-15 Idec Pharma Corp Therapeutische verwendung von chimerischen und markierten antikörper gegen menschlichen b lymphozyt beschränkter differenzierung antigen für die behandlung von b-zell-lymphoma
EP2275540B1 (en) * 1999-04-09 2016-03-23 Kyowa Hakko Kirin Co., Ltd. Method for controlling the activity of immunologically functional molecule
US20030165502A1 (en) * 2000-06-13 2003-09-04 City Of Hope Single-chain antibodies against human insulin-like growth factor I receptor: expression, purification, and effect on tumor growth
US7553485B2 (en) * 2002-01-18 2009-06-30 Pierre Fabre Medicament Anti-IGF-IR and/or anti-insulin/IGF-I hybrid receptors antibodies and uses thereof
US7241444B2 (en) * 2002-01-18 2007-07-10 Pierre Fabre Medicament Anti-IGF-IR antibodies and uses thereof
MXPA04011624A (es) * 2002-05-24 2005-03-07 Schering Corp Anticuerpo neutralizante humano anti-igfr.
CA2519113C (en) * 2003-04-02 2012-06-05 F. Hoffmann-La Roche Ag Antibodies against insulin-like growth factor i receptor and uses thereof
AR046071A1 (es) * 2003-07-10 2005-11-23 Hoffmann La Roche Anticuerpos contra el receptor i del factor de crecimiento de tipo insulinico y los usos de los mismos
US20070142627A1 (en) * 2003-08-01 2007-06-21 Chugai Seiyaku Kabushiki Kaisha Sugar-chain-altered anti-hm1.24 antibody
EP1693069B1 (en) * 2003-10-10 2013-07-24 Chugai Seiyaku Kabushiki Kaisha Remedy for solid tumor

Also Published As

Publication number Publication date
BRPI0710185B1 (pt) 2020-01-14
BRPI0710185A2 (pt) 2011-08-09
NZ571414A (en) 2011-12-22
CA3081707A1 (en) 2007-10-18
US20080014203A1 (en) 2008-01-17
IL194397A (en) 2014-04-30
RU2008144290A (ru) 2010-05-20
AU2007236199A1 (en) 2007-10-18
EP2007810B1 (en) 2013-02-13
CA2647181A1 (en) 2007-10-18
RU2541765C2 (ru) 2015-02-20
CA2647181C (en) 2020-08-11
KR20120028396A (ko) 2012-03-22
WO2007115814A3 (en) 2008-01-10
AU2007236199B2 (en) 2013-07-25
EP2363417A1 (en) 2011-09-07
BRPI0710185A8 (pt) 2019-01-22
BRPI0710185B8 (pt) 2021-05-25
JP2009533367A (ja) 2009-09-17
MX2008012950A (es) 2008-10-15
KR20080113233A (ko) 2008-12-29
ZA200808597B (en) 2009-11-25
ES2403075T3 (es) 2013-05-13
CN101421305A (zh) 2009-04-29
WO2007115814A2 (en) 2007-10-18
IL194397A0 (en) 2011-08-01
NO20084082L (no) 2008-11-06
AR060592A1 (es) 2008-07-02
JP4718634B2 (ja) 2011-07-06
CN101421305B (zh) 2013-05-15
EP2007810A2 (en) 2008-12-31
KR101276513B1 (ko) 2013-06-21
ECSP088816A (es) 2008-11-27
CR10301A (es) 2008-10-29

Similar Documents

Publication Publication Date Title
MX2008012950A (es) Anticuerpos contra el receptor del factor i de crecimiento de tipo insulina y sus usos.
TW200833712A (en) Antibodies against insulin-like growth factor I receptor and uses thereof
CA2647288C (en) A cho-dg44 derivative cell line expressing an antibody against insulin-like growth factor receptor 1
WO2004087756A3 (en) Antibodies against insulin-like growth factor i receptor and uses thereof
WO2008134724A3 (en) Methods for administering anti-il-5 antibodies
WO2008006554A3 (en) Glyco-engineered antibodies
UA93488C2 (uk) Композиція анти-гліпікан 3-антитіл, що мають модифікований цукровий ланцюг
EP2365006A3 (en) Novel anti-IGF-IR antibodies and uses thereof
WO2008036341A3 (en) Compositions and methods relating to glucagon receptor antibodies
SG10201407388XA (en) Humanized anti-cxcr5 antibodies, derivatives thereof and their uses
TN2009000245A1 (en) Human antibodies to human delta like ligand 4
WO2005003175A3 (en) Aglycosyl anti-cd154 (cd40 ligand) antibodies and uses thereof
WO2008091641A3 (en) Compositions and methods for diagnosing and treating cancer
IL194550A (en) Isolated antibodies or their fragments that bind to human protein tyrosine phosphate in a cell, their pharmaceutical preparations and their use
WO2004010947A3 (en) Humanized antibodies against human 4-1bb
NZ616992A (en) Anti-ilt7 antibody
WO2008145137A3 (en) Recombinant non glycosylated monovalent half-antibodies obtained by molecular engineering
NZ600262A (en) Anti-her3 antibodies and uses thereof
PT1383785E (pt) Anticorpo recombinante específico de tumores e utilização deste
WO2007071422A3 (en) Pharmaceutical antibody compositions with resistance to soluble cea
MX2009005103A (es) Conjugado anti-idiotipo y su uso como un estandar en un inmunoensayo.
WO2005120557A3 (en) Inhibition of macrophage-stimulating protein receptor (ron)
WO2005090406A3 (en) Antibodies binding to ephb4 for inhibiting angiogenesis and tumor growth
WO2006029220A3 (en) Combination therapy with anti-ctla4 and anti-4-1bb antibodies
EP1688437A4 (en) ANTIBODY COMPOSITION SPECIFICALLY BINDING TO IL-5 RECEPTOR